Rheumatoid Arthritis 540737-29-9 Tofacitinib Citrate Intermediate Tofacitinib Citrate

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: D-Sung Tofacitinib Citrate
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Tofacitinib Citrate
• Name: Tofacitinib Citrate Powder
• Appearance: White Powder
• Colour: White
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical
• Specific: COA
• Test Method: HPLC
• CAS No.: 540737-29-9
• Mf: C16h20n6o.C6h8o7
• MW: 504.497
• Shelf Life: 2 Years
• Melting Point: 201 C
• Storage Tempera: Room Temp
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 100kg/Month

Product Description

Rheumatoid Arthritis 540737-29-9 Tofacitinib Citrate Intermediate Tofacitinib Citrate

 

Product Description

Product Details

Product Name	Tofacitinib Citrate
Appearance	White Powder
CAS No.	540737-29-9
MF	C16h20n6o.C6h8o7
MW	504.497

Tofacitinib citrate, also known as 3- [(3R, 4R) -4-methyl-3- [methyl - (7H-pyrrolo [2,3-d] pyrimidin-4-yl) amino] piperidin-1-yl] -3-oxopropionitrile citrate, is a novel Janus kinase inhibitor developed by in the United States. It can be used in combination with methotrexate to treat active rheumatoid arthritis with insufficient response to tumor necrosis factor inhibitors.

Application&Function

Tofacitinib citrate combined with methotrexate is used to treat active rheumatoid arthritis with insufficient response to tumor necrosis factor inhibitors. Medications for treating rheumatoid arthritis Used for adult patients with moderate to severe active rheumatoid arthritis (RA) who have insufficient or intolerant response to methotrexate treatment. This product is a Janus kinase inhibitor. Tofacitinib citrate is used in adult patients with moderate to severe active rheumatoid arthritis (RA) who have insufficient or intolerant response to methotrexate treatment. Xeljanz can be used as a monotherapy or in combination with methotrexate or other non biological disease relieving antirheumatic drugs (DMARD). This drug should not be used in combination with biological DMARDs or strong immunosuppressants such as azathioprine and cyclosporine.

Specification